A Comparative Study of Intravenous Immunoglobulin and Subcutaneous Immunoglobulin in Adult Patients with Primary Immunodeficiency Diseases: A Systematic Review and Meta-Analysis

References

• Borte S, Wang N, Oskarsdóttir S, et al. Newborn screening for primary immunodeficiencies: beyond SCID and XLA. Ann N Y Acad Sci. 2011;1246:118–130.
   PubMed Web of Science ®Google Scholar
• Borte S, vonDöbeln U, Hammarström L. Guidelines for newborn screening of primary immunodeficiency diseases. Curr Opin Hematol. 2013;20:48–54.
   PubMed Web of Science ®Google Scholar
• Aghamohammadi A, Moin M, Rezaei N. History of primary immunodeficiency diseases in Iran. Iran J Pediatr. 2010;20:16.
   PubMed Web of Science ®Google Scholar
• Rezaei N, Aghamohammadi A, Notarangelo LD, editors. Primary immunodeficiency diseases: definition, diagnosis, and management. Berlin: Springer Science & Business Media; 2008 Aug 6.
   Google Scholar
• Rezaei N, Abolhassani H, Aghamohammadi A, et al. Indications and safety of intravenous and subcutaneous immunoglobulin therapy. Expert Rev Clin Immunol. 2011;7:301–306.
   PubMed Web of Science ®Google Scholar
• Peter JG, Chapel H. Immunoglobulin replacement therapy for primary immunodeficiencies. Immunotherapy. 2014;6:853–869.
   PubMed Web of Science ®Google Scholar
• Gardulf A, Nicolay U, Asensio O, et al. Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. J Allergy Clin Immunol. 2004;114 (4):936–942.
   PubMed Web of Science ®Google Scholar
• Liu Z, Albon E, Hyde C. The effectiveness and cost effectiveness of immunoglobulin replacement therapy for primary immunodeficiency and chronic lymphocytic leukaemia: a systematic review and economic evaluation. Birmingham: University of Birmingham, Department of Public Health and Epidemiology; 2005.
   Google Scholar
• Wasserman RL. A new intravenous immunoglobulin (BIVIGAM®) for primary humoral immunodeficiency. Expert Rev Clin Immunol. 2014;10:325–337.
   PubMed Web of Science ®Google Scholar
• Berger M. Principles of and advances in immunoglobulin replacement therapy for primary immunodeficiency. Immunol Allergy Clin North Am. 2008;28:413–437.
   PubMed Web of Science ®Google Scholar
• Hammarstrom L, Gardulf A, Edvard Smith CI. Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion. Lancet. 1991;338:162–166.
   PubMed Web of Science ®Google Scholar
• Hansen S, Gustafson R, Smith C, et al. Express subcutaneous IgG infusions: decreased time of delivery with maintained safety. Clin Immunol. 2002;104:237–241.
   PubMed Web of Science ®Google Scholar
• Gardulf A. Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route. BioDrugs. 2007;21:105–116.
   PubMed Web of Science ®Google Scholar
• Gardulf A, Andersen V, Björkander J, et al. Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: safety and costs. Lancet. 1995;345:365–369.
   PubMed Web of Science ®Google Scholar
• Chapel HM, Spickett GP, Ericson D, et al. The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol. 2000;20:94–100.
   PubMed Web of Science ®Google Scholar
• Fasth A, Nyström J. Safety and efficacy of subcutaneous human immunoglobulin in children with primary immunodeficiency. Acta Paediatr. 2007;96:1474–1478.
   PubMed Web of Science ®Google Scholar
• Jolles S, Orange JS, Gardulf A, et al. Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease. Clin Exp Immunol. 2015;179:146–160.
   PubMed Web of Science ®Google Scholar
• Abolhassani H, Sadaghiani MS, Aghamohammadi A, et al. Home-based subcutaneous immunoglobulin versus hospital-based intravenous immunoglobulin in treatment of primary antibody deficiencies: systematic review and meta analysis. J Clin Immunol. 2012;32:1180–1192.
   PubMed Web of Science ®Google Scholar
• Bezrodnik L, Gómez Raccio A, Belardinelli G, et al. Comparative study of subcutaneous versus intravenous IgG replacement therapy in pediatric patients with primary immunodeficiency diseases: a multicenter study in Argentina. J Clin Immunol. 2013;33:1216–1222.
   PubMed Web of Science ®Google Scholar
• Shapiro R. Subcutaneous immunoglobulin (16 or 20%) therapy in obese patients with primary immunodeficiency: a retrospective analysis of administration by infusion pump or subcutaneous rapid push. Clin Exp Immunol. 2013;173:365–371.
   PubMed Web of Science ®Google Scholar
• Kanegane H, Imai K, Yamada M, et al. Efficacy and safety of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency diseases. J Clin Immunol. 2014;34:204–211.
   PubMed Web of Science ®Google Scholar
• Soler-Palacín P, Gasó-Gago I, Fernández-Polo A, et al. Intravenous and subcutaneous immunoglobulin replacement: a two-way road. Optimizing healthcare quality in patients with primary immunodeficiencies. J Clin Immunol. 2014;34:1015–1017.
   PubMed Web of Science ®Google Scholar
• Vultaggio A, Azzari C, Milito C, et al. Subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency in routine clinical practice: the VISPO prospective multicenter study. Clin Drug Investig. 2015;35:179–185.
   PubMed Web of Science ®Google Scholar
• Empson MB, Tang MLK, Pearce LKC, et al. Efficacy, safety and pharmacokinetics of a novel subcutaneous immunoglobulin, evogam®, in primary immunodeficiency. J Clin Immunol. 2012;32:897–906.
   PubMed Web of Science ®Google Scholar
• Wasserman RL, Melamed I, Kobrynski L, et al. Efficacy safety, and pharmacokinetics of a 10% liquid immune globulin preparation (GAMMAGARD LIQUID, 10%) administered subcutaneously in subjects with primary immunodeficiency disease. J Clin Immuno. 2011;31:323–331.
   PubMed Web of Science ®Google Scholar
• Jolles S, Bernatowska E, De Gracia J, et al. Efficacy and safety of Hizentra® in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy. J Clin Immunol. 2011;141:90–102.
   Web of Science ®Google Scholar
• Borte M, Quinti I, Soresina A, et al. Efficacy and safety of subcutaneous vivaglobin® replacement therapy in previously untreated patients with primary immunodeficiency: a prospective, multicenter study. J Clin Immunol. 2011;31:952–961.
   PubMed Web of Science ®Google Scholar
• Wasserman RL, Melamed I, Nelson Jr. RP, et al. Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency. Clin Pharmacokinet. 2011;50:405–414.
   PubMed Web of Science ®Google Scholar
• Wasserman RL1, Irani AM, Tracy J, et al. Pharmacokinetics and safety of subcutaneous immune globulin (human), 10% caprylate/chromatography purified in patients with primary immunodeficiency disease. Clin Exp Immunol. 2010;161:518–526.
   PubMed Web of Science ®Google Scholar
• Hoffmann F, Grimbacher B, Thiel J, et al. Home-based subcutaneous immunoglobulin G replacement therapy under real-life conditions in children and adults with antibody deficiency. Eur J Med Res. 2010;15:238.
   PubMed Web of Science ®Google Scholar
• Shapiro R. Subcutaneous immunoglobulin therapy by rapid push is preferred to infusion by pump: a retrospective analysis. J Clin Immuno. 2010;30:301–307.
   PubMed Web of Science ®Google Scholar
• Hagan JB, Fasano MB, Spector S, et al. Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency. J Clin Immuno. 2010;30:734–745.
   PubMed Web of Science ®Google Scholar
• Quinti I, Soresina A, Agostini C, et al. Prospective study on CVID patients with adverse reactions to intravenous or subcutaneous IgG administration. J Clin Immunol. 2008;28:263–267.
   PubMed Web of Science ®Google Scholar
• Gelfand EW, Hanna K. Safety and tolerability of increased rate of infusion of intravenous immunoglobulin G, 10% in antibody-deficient patients. J Clin Immunol. 2006;26:284–290.
   PubMed Web of Science ®Google Scholar
• Ochs HD, Gupta S, Kiessling P, et al. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol. 2006;26:265–273.
   PubMed Web of Science ®Google Scholar
• Gardulf A, Nicolay U, Asensio O, et al. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies—a prospective, multi-national study. J Clin Immunol. 2006;26:177–185.
   PubMed Web of Science ®Google Scholar
• Eijkhout H, Van Den Broek P, Van Der Meer J. Substitution therapy in immunodeficient patients with anti-IgA antibodies or severe adverse reactions to previous immunoglobulin therapy. Neth J Med. 2003;61:213–217.
   PubMed Web of Science ®Google Scholar
• Gaspar J, Gerritsen B, Jones A. Immunoglobulin replacement treatment by rapid subcutaneous infusion. Arch Dis Child. 1998;79:48–51.
   PubMed Web of Science ®Google Scholar
• Schiff RI, Williams LW, Nelson RP, et al. Multicenter crossover comparison of the safety and efficacy of Intraglobin-F with Gamimune-N, Sandoglobulin, and Gammagard in patients with primary immunodeficiency diseases. J Clin Immunol. 1997;17:21–28.
   PubMed Web of Science ®Google Scholar
• McCormack PL. Immune globulin subcutaneous (Human) 20%: in primary immunodeficiency disorders. Drugs. 2012;72:1087–1097.
   PubMed Web of Science ®Google Scholar
• Lemieux R, Bazin R, Néron S. Therapeutic intravenous immunoglobulins. Mol Immunol. 2005;42:839–848.
   PubMed Web of Science ®Google Scholar
• Berger M. Subcutaneous immunoglobulin replacement in primary immunodeficiencies. Clin Immunol. 2004;112:1–7.
   PubMed Web of Science ®Google Scholar
• Högy B, Keinecke HO, Borte M. Pharmacoeconomic evaluation of immunoglobulin treatment in patients with antibody deficiencies from the perspective of the German statutory health insurance. Eur J Health Econ. 2005;6:24–29.
   PubMedGoogle Scholar
• Haddad L, Perrinet M, Parent D, et al. Economic evaluation of at home subcutaneous and intravenous immunoglobulin substitution. La Revue De Medecine Interne/Fondee… Par La Societe Nationale Francaise De Medecine Interne, Rev Med Interne. 2006;27:924–926.
   PubMed Web of Science ®Google Scholar
• Nicolay U, Kiessling P, Berger M, et al. Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home. J Clin Immuno. 2006;26:65–72.
   PubMed Web of Science ®Google Scholar
• Membe SK, Ho C, Cimon K, et al. Economic assessment of different modalities of immunoglobulin replacement therapy. Immunol Allergy Clin North Am. 2008;28:861–874.
   PubMed Web of Science ®Google Scholar
• Skoda-Smith S, Torgerson TR, Ochs HD. Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease. Ther Clin Risk Manag. 2010;6:1.
   PubMed Web of Science ®Google Scholar
• Borte M, Pac M, Serban M, et al. Efficacy and safety of Hizentra ®, a new 20% immunoglobulin preparation for subcutaneous administration, in pediatric patients with primary immunodeficiency. J Clin Immunol. 2011;31:752–761.
   PubMed Web of Science ®Google Scholar
• Ho C, Membe S, Cimon K. An overview of subcutaneous vs. intravenous immunoglobulin for primary immunodeficiencies: systematic review and economic analysis. CADTH. HTA. 2008;36:1–8.
   Google Scholar